



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## SKLB-163

<b>Cat. No.:</b>	HY-120429
<b>CAS No.:</b>	1255099-06-9
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>16</sub> ClN <sub>3</sub> O <sub>2</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	405.92
<b>Target:</b>	Apoptosis
<b>Pathway:</b>	Apoptosis
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	SKLB-163 is an orally active inhibitor for Rho GDP-dissociation (RhoGDI). SKLB-163 inhibits highly expressed RhoGDI tumor cell proliferation and migration, and increases radiosensitivity of tumor cells. SKLB-163 induces cancer cell Apoptosis <sup>[1][2]</sup> .
<b>In Vitro</b>	SKLB-163 (0-20 μM, 48 h) inhibits proliferation and migration of nasopharyngeal carcinoma (NPC) cells, and sensitizes cells to irradiation <sup>[1]</sup> . SKLB-163 (0-20 μM, 48 h) shows cytotoxicity effect in A375, SPC-A1, SW620, HeLa, PC-3 cells <sup>[2]</sup> . SKLB-163 (0-2.5 μM, 48 h) induces A375 cell apoptosis and inhibits colony information <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	SKLB-163 (25-100 mg/kg, i.g., once daily for 30 days) inhibits tumor growth and ascites formation, and inhibits liver and lung metastasis in NPC lung metastatic mice model <sup>[1]</sup> . SKLB-163 (50 mg/kg, once daily. from the 6th day of SKLB-163 administration, 3 Gy radiation once per day for 3 days) sensitizes NPC tumor to irradiation in CNE-2 and C666-1 subcutaneous xenograft mice models <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>Animal Model:</b>	NPC lung metastatic model: transplanting NPC cells C666-1 into the livers of BALB/c nude mice <sup>[1]</sup>
<b>Dosage:</b>	25, 50, 100 mg/kg
<b>Administration:</b>	intragastric administration, once daily for 30 days
<b>Result:</b>	Reduced tumor size by 33.5% (25 mg/kg), 53.6% (50 mg/kg), 81.6% (100 mg/kg), respectively. Ascited formation by 33.9% (25 mg/kg), 58.7% (50 mg/kg), 82.2% (100 mg/kg). Inhibited liver or lung metastasis.

### REFERENCES

[1]. He J, et al. Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway. *Radiother Oncol.* 2018 Oct;129(1):30-37.

---

[2]. Peng X, et al. SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway. Cell Death Dis. 2014 Mar 27;5(3):e1143.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA